clinical trial · NCT00662909
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Urinary Bladder, OveractiveMirabegronPlacebo
brief summary
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
started
Mar 28, 2008
primary completion
Apr 22, 2009
completion
Apr 22, 2009
last updated
Nov 20, 2024
official title
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol